CLSPN and familial pancreatic carcinoma: Based on these data, it can be concluded that celastrol treatment decreased the global RNA m6A modification, especially reduced the mRNA m6A modification of Claspin and Bcl-2 probably by downregulating METTL3, leading to the downregulation of Claspin and Bcl-2 in pancreatic cancer cells.